Direct answer:The FDA classification looks primarily at the statutory definition of products and intended use. Similar products may be subject to different regulatory paths because of formulas, uses, or labels, or may be subject to multiple regulatory regimes. It has not yet been determined that products are exported in the United States to food, supplements, medicines, instruments, cosmetics, or radioactive products.
Which products and enterprises do this apply to?
The FDA classification looks primarily at the statutory definition of products and intended use. Similar products may be subject to different regulatory paths due to formulations, uses or labels, or may be subject to multiple regulatory regimes.
The product categories should be checked in conjunction with product uses, constituents or technical characteristics, labelling claims, production/import activities and corporate roles; When the information is insufficient, the facts are identified.
What are the rules or concepts?
The FDA path judgement begins with the intended use, composition/technology, declaration, business activity and market role and cannot be determined by product names alone.
The official requirements described in this document are based on the relevant bills, regulations and the official FDA page. The information and process proposals set out below are part of the site’s substantive recommendations and do not replace statutory obligations.
How do you determine whether you need to do this?
- Identify legal categories of products, intended uses and target markets.
- Lists manufacturers, brands/labellers, importers and U.S. agents.
- Identification of specific regulatory actions against official scope of application, exemptions and exceptions; Retention issues in cases of uncertainty and further verification.
What needs to be prepared, and how do you usually handle it?
Collection of formulations/specifications, working principles, target users, end-use declarations, labels and production activities; Comparing FDA product classifications with official rules; Identification of manufacturing/import/brand roles; The records are still to be added and the path is to be determined.
- Product uses, formulations/descriptions, labelling and manufacturing information;
- (a) Information on the facility and the subject of the enterprise, the responsible party and the records of the submission;
- The official rules are based, the questions to be checked and the internal authority responsible.
Common error zones, exceptions and risk boundaries
This text can only be used for the first screening; Portfolio products, border products, therapeutic declarations and specific components require reference to specific legislation or appropriate communication to the FDA.
Real project cases are not publicly available and therefore no fictional client cases are added. Product boundaries or special exemptions should be judged by specific facts and official documents.
Official sources are checked with recent information.
Date of official data check: 2026-11-04. The applicability should be re-checked after updating the FDA page or legislation.
What's next?
The product, the role of the enterprise, the target market and existing records are collated and the path is checked against the official information listed here. You can also see FDA Knowledge Base、Scope of related services| Or through Contact PageSubmission of specific information.
Continue reading and preparation
- Chinese medicinal herbs and botanicals in the U.S.: supplement, food and drug pathways
- What's FDA authentication? U.S. compliance path and judgement for five categories of products
Further consolidation of project information is availableFDA Registration and Compliance Services Overview; The scope, processing cycles and costs are shown on the corresponding service page.